Metoprolol succinate er 50 mg
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Metoprolol Succinate ER 50 mg: Pharmacokinetics, Efficacy, and Safety
Pharmacokinetics of Metoprolol Succinate ER 50 mg
Metoprolol succinate extended-release (ER) tablets are designed to provide a controlled release of the medication over a 24-hour period. Studies comparing the pharmacokinetics (PK) of brand name versus generic formulations of metoprolol ER have shown that the primary PK endpoints, such as the area under the concentration-time curve (AUC) and maximum concentration (Cmax), are similar between products. However, the time to maximum concentration (Tmax) can vary significantly, which may affect the drug's impact on autonomic balance over the dosing interval.
Bioequivalence and Dosage Considerations
Research has established the bioequivalence of 50 mg metoprolol succinate ER tablets under fasting conditions in healthy adults. The pharmacokinetic profiles of test and reference metoprolol ER tablets were found to be within the acceptable bioequivalence range, indicating that both formulations are interchangeable in clinical practice. Additionally, the controlled-release formulation of metoprolol succinate provides a more consistent plasma concentration over time compared to conventional metoprolol tartrate tablets, which can result in more stable therapeutic effects.
Efficacy in Hypertension and Heart Disease
Metoprolol succinate ER is effective in managing hypertension and ischemic heart disease (IHD). In patients with stable IHD, higher doses of metoprolol (up to 200 mg/day) were more effective in achieving target heart rates and improving quality of life compared to lower doses (50-100 mg/day). Furthermore, metoprolol succinate ER has been shown to provide significant hemodynamic benefits in congestive heart failure patients, with similar efficacy to metoprolol tartrate but with the convenience of once-daily dosing.
Safety and Tolerability
The safety profile of metoprolol succinate ER is well-documented. In a study involving hypertensive subjects, metoprolol succinate ER was found to increase plasma asymmetric dimethylarginine (ADMA) levels in a dose-dependent manner, which could have implications for vascular health. However, the drug was generally well-tolerated, with no significant differences in adverse events between the test and reference formulations. Additionally, long-term use of metoprolol succinate ER in heart failure patients was associated with improved left ventricular ejection fraction and a reduction in ventricular ectopic beats, indicating its safety and efficacy in this population.
Conclusion
Metoprolol succinate ER 50 mg is a reliable and effective option for managing hypertension and heart disease. Its controlled-release formulation ensures stable plasma concentrations, enhancing therapeutic outcomes and patient compliance. The drug's safety and tolerability make it a suitable choice for long-term management of cardiovascular conditions.
Sources and full results
Most relevant research papers on this topic